1. CARTAGENA PROTOCOL ON BIOSAFETY
Protocol to the Convention on Biological Diversity
Art. 8(g): Establish or maintain means to regulate the risks associated with the use of living modified organisms taking also into account the risks to human health.
Art. 19(3): consider the need for and modalities of a protocol in the field of safe use of any living modified organism. . .

2. CPB PROVISIONS
• Scope includes all LMO’s but excludes pharmaceuticals for humans (Art. 5)
Advance notification to importing party (Annex I & III information)
• Advance informed agreement (AIA) - Timeframes
• AIA for LMO-FFP’s - Annex II & Annex III
(Art. 11) - information sharing on BCH
- legal requirement for accuracy of information
• Legislative measures to ensure effective implementation
• Designation of focal point, competent authority(ies), BCH

3. ACCESSION TO CPB: IMPLICATIONS
EXISTING & DEVELOPING LEGISLATION - GMO Act (Act 15 of 1997) Foodstuffs, Cosmetics & Disinfectants Act (Act 54 0f 1972) • CAPACITY AND RESOURCE COMMITMENT • PUBLIC AWARENESS AND PARTICIPATION - promote & facilitate public awareness - ensure access to information - consult public in decision-making

4. CURRENT STATUS OF CPB
• > 170 Countries negotiated • Open for signature June June • Enters into force 90 days after 50th ratification (or 90 days after individual ratification/accession) • 10 Ratifications/accessions to date